Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsZing Health Osteoporosis Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentZing HealthPolicy 5826-D

    Medicare Part B Step Therapy Osteoporosis-Bone Density

    Customize your policy alerts

    Sign up for zing_health Policy 5826-D alerts

    Get alerted when Policy 5826-D changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs Medicare Part B coverage of specified osteoporosis products for Zing Health members. It identifies preferred products and establishes a prior authorization exception process for the non-preferred product, in addition to applicable Medicare coverage and utilization management requirements.

    Policy Summary
    PayerZing Health
    PolicyMedicare Part B Step Therapy Osteoporosis-Bone Density
    Policy CodePolicy 5826-D
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization for an Evenity exception and document prior use or the applicable clinical exceptions.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3preferred osteoporosis products
    1non-preferred osteoporosis product
    365 daysprior-use lookback
    35 mL/mincreatinine clearance threshold

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Medicare Part B
    applicable benefit

    Non-Preferred Evenity Exception

    Non-preferred Evenity exception

    Coverage for the non-preferred product is provided when the member is requesting treatment for an FDA-approved indication for the preferred products and meets at least one of the following criteria:

    ONE of

    • Prior use of the non-preferred product: Member has received treatment with the non-preferred product within the past 365 days.within the past 365 days
    • Clinical exception to preferred therapy

      • Jubbonti or Prolia exception: Member has a documented inadequate response, intolerable adverse event, contraindication, or clinical reason to avoid Jubbonti or Prolia.
      • Zoledronic acid exception: Member has a documented inadequate response, intolerable adverse event, or contraindication to zoledronic acid.

        Example: creatinine clearance less than 35 mL/min.

    Clinical Threshold

    Creatinine Clearance
    Creatinine clearance thresholdLess than 35 mL/min

    Provider Requirements and Review

    Prior Authorization

    Prior Authorization for Non-Preferred Evenity

    Evenity (romosozumab-aqqg) is non-preferred and requires prior authorization. Submit an exception request when the member has received Evenity within the past 365 days or meets the required clinical-exception criteria for avoiding preferred products. Review remains subject to applicable NCDs, LCDs, and Medicare Part B utilization-management programs.

    • The member must be requesting treatment for an FDA-approved indication for the preferred products.
    • An exception may be supported by prior Evenity treatment within the past 365 days, or by documented clinical circumstances that exclude use of the preferred products.
    Prior Authorization

    Preferred Products May Require Clinical Review

    Preferred osteoporosis products may still require clinical prior authorization review. Do not assume that preferred status eliminates the need to submit clinical information or satisfy applicable coverage requirements.

    • Preferred products: Jubbonti (denosumab-bbdz), Prolia (denosumab), and zoledronic acid.

    Policy Background

    This policy addresses osteoporosis products administered under the Medicare Part B benefit. It informs prescribers of the plan’s preferred products and establishes an exception process for the non-preferred product through prior authorization. Preferred products are Jubbonti (denosumab-bbdz), Prolia (denosumab), and zoledronic acid; Evenity (romosozumab-aqqg) is non-preferred. Preferred-product sequencing applies in addition to applicable Medicare coverage requirements, including National Coverage Determinations, Local Coverage Determinations, and Medicare Part B utilization-management programs.

    Initial Evenity Exception

    Initial Evenity exception

    Coverage for the non-preferred product is provided when the member meets one of the following criteria:

    ONE of

    • Prior Evenity treatment: Member has received treatment with Evenity within the past 365 days.within the past 365 days
    • Exception to preferred products

      • Jubbonti or Prolia cannot be used: Member has a documented inadequate response, intolerable adverse event, contraindication, or clinical reason to avoid Jubbonti or Prolia.
      • Zoledronic acid cannot be used:

    Preferred Product Sequence

    SequenceProduct(s)Plan statusCoverage and authorization implications
    Step 1Jubbonti (denosumab-bbdz); Prolia (denosumab); zoledronic acidPreferredUse of preferred products is required before coverage of Evenity. Preferred products may still require a clinical prior authorization review.
    After preferred therapy or approved exceptionEvenity (romosozumab-aqqg)Non-preferred; exception requiredPrior authorization is required. Coverage may be available when the member received Evenity within the past 365 days or has documented exceptions to Jubbonti or Prolia and to zoledronic acid.
    Policy Summary
    PayerZing Health
    PolicyMedicare Part B Step Therapy Osteoporosis-Bone Density
    Policy CodePolicy 5826-D
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization for an Evenity exception and document prior use or the applicable clinical exceptions.
    SourceLink
    On This Page
    Non-Preferred Evenity ExceptionClinical ThresholdProvider Requirements and ReviewPolicy BackgroundInitial Evenity ExceptionPreferred Product Sequence

    Unsupported block type: step_therapyถcallout

    Documentation Required

    Document the Clinical Exception

    Exception requests must include documentation supporting the clinical rationale for avoiding preferred therapy. Document prior treatment and, as applicable, inadequate response, an intolerable adverse event, a contraindication, or another clinical reason to avoid Jubbonti or Prolia; also document inadequate response, an intolerable adverse event, or a contraindication to zoledronic acid.

    • For zoledronic acid, include relevant clinical detail such as creatinine clearance less than 35 mL/min when applicable.
    • Documentation should support the specific exception rationale and the member's treatment history.
    Denial Risk

    Exception Requirements Must Be Met

    If the member does not meet or cannot document the non-preferred-product exception requirements, the request for Evenity may be denied. Ensure the submission establishes either qualifying prior Evenity treatment within 365 days or all required elements of the clinical exception.

    • For the clinical-exception pathway, documentation is required for both: avoidance of Jubbonti or Prolia and avoidance of zoledronic acid.
    • Failure to satisfy the exception criteria or provide supporting documentation creates denial risk.
    Member has a documented inadequate response, intolerable adverse event, or contraindication to zoledronic acid.

    Example: creatinine clearance less than 35 mL/min.